R. Brugnoli, T. Arcangeli, P. Pancheri- Vol. 5, Dicembre 1999, num.4
Testo Immagini Bibliografia Summary Riassunto Indice
Indagine conoscitiva sui disturbi
dello spettro schizofrenico
A survey of schizophrenic spectrum disorders
1 Pancheri P, e Coll.
Rivista italiana di psichiatria. Linee guida per la terapia farmacologica
della schizofrenia.
1995;30:2.
2 American Psychiatric Association.
Linee guida per il trattamento della schizofrenia.
Masson 1999.
3 Pancheri P, Marconi PL.
Dimensioni della schizofrenia e intervento terapeutico.
In: Pancheri P. Farmacoterapia del disturbo schizofrenico: tattica
e strategia. Scientific Press 1996 Firenze.
4 Raja M.
Farmacoterapia della schizofrenia.
Piccin, Padova 1995.
5 Kane JM.
Treatment programme and long term outcome in chronic schizophrenia.
Acta Psychiatrica Scandinavica (suppl)1990;37:16-24.
6 Jenner P, Marsden CD.
Antiparkinsonian and antidyskinetic drugs.
In: Tyrer PJ, ed. Drugs in psychiatric practice. London: Butterworths
1982;82-125.
7 Kane J, Honigfeld G, Singer J, Meltzer H, The clozaril collaborative study
group.
Clozapine for the treatment-resistant schizophrenic. A double blind comparision
with chlorpromazine.
Archives of General Psychiatry 1988A;45:789-796.
8 Fischer-Cornelssen KA, Ferner UJ.
An example of european multicenter trials: multispectral analysis of clozapine.
Psychopharmacology Bulletin 1976;12:34-39.
9 Claghorn J, Honigfeld G, Abuzzahab FS.
The risk and benefits of clozapine vs chlorpromazine.
Journal of Clinical Psychopharmacology 1987;7:377-384.
10 Chouinard G, Jones B, Remington GI.
A canadian multicenter placebo-controlled study of fixed doses of Risperidone
and haloperidol in the treatment of chronic schizophrenic patients.
Journal of Clinical Psychopharmacology 1993;13,1:25-40.
11 Marder SR, Meibach RC.
Risperidone in the treatment of schizophrenia.
American Journal of Psychiatry 1994;151:825-835.
12 Peuskens J.
Risperidone in the treatment of patients with chronic schizophrenia: a
multi-national, multi-centre, double-blind, parallel-group study versus haloperidol.
British Journal of Psychiatry 1995;166:712-726.
13 Carman J.
Risperidone in treatment of negative symptoms of schizophrenia.
Internal Clinical Psychopharmacology 1995;10:207-213.
14 Addington DE, Jones B, Bloom D, Chouinard G, Remington G, Albright P.
Reduction of hospital days in chronic schizophrenic patients treated with
Risperidone: a retrospective study.
Clinical Therapeutics 1993;15,5:917-926.
15 Guest JF, e Coll.
Pharmacoeconomic evaluation of long-term treatment with Risperidone for
patients with chronic schizophrenia.
British Journal of Medicine Econ 1996;10:59-67.
16 Jones B.
Effect of Risperidone treatment on hospitalitasion status in patients with
chronic schizophrenia.
Proc 9th World Congress of Psychiatry, Rio de Janeiro, 6-12 June 1993;26-32.
17 Conley R, e Coll.
Re-hospitalitazion rate of recently discharged patients treated with Risperidone.
Maryland Rehospitalisation Data 1997.
18 Borison RL, Diamond BI, Pathiraja A, Meibach RC.
Clinical overview of Risperidone.
In: Meltzer HY, ed. Novel antipsychotic drugs. New York: Raven
Press 1992:233-239.
19 Borison RL.
Changing antipsychotic medication: guidelines on the transition to treatment
with Risperidone.
Clinical Therapeutics 1996;18(4):592-607.
20 Pogue-Guile MF, Harrow M.
Negative symptoms in schizophrenia: their longitudinal course and prognostic
importance.
Schizophrenia Bulletin 1985;11:427-439.
21 Borison RL, Pathiraja AP, Diamond BI, Meibach RC.
Risperidone: clinical safety and efficacy in schizophrenia.
Psychopharmacology Bulletin 1992;28:213-218.
22 Pogue-Guile MF.
The prognostic significance of negative symptoms in schizophrenia.
British Journal of Psychiatry 1989;155(Suppl 7):123-127.
23 Keefe RSE, Mohs RC, Losonczy MF, e Coll.
Characteristics of very poor outcome schizophrenia.
American Journal of Psychiatry 1987;144:889-895.
24 Owens DGC.
Extrapyramidal side effects and tolerability of Risperidone: a review.
Journal of Clinical Psychiatry 1994;55 (Suppl):29-35.
25 Carman J.
Risperidone in the treatment of negative symptoms of schizophrenia.
Internal Clinical Psychopharmacology 1995;10:207-213.
26 Marder SR.
The effects of Risperidone on dimension of schizophrenia derived by factor
analysis combine the results of the north american psychiatry.
Journal of Clinical Psychopharmacology 1997;58,12:538-546.
27 Rush AJ, Rago WV, Crisman ML, e Coll.
Medication treatment for the severely and persistently mentally ill.
The Texas medication algorithm Project 1999;60:284-291.
28 Expert consensus guidelines series: treatment of schizophrenia.
Journal of Clinical Psychiatry 1996;57(suppl 12B):1-58.
29 American Psychiatric Association.
Practice guidelines for the treatment of patients with schizophrenia.
American Journal of Psychiatry 1997;154 (suppl 4):1-63.
30 Miller LA, Chiles JA, Chiles JK, e Coll.
The Texas medication algorithm project (TMAP). Schizophrenia algorithms.
Journal of Clinical Psychiatry 1999;60,10:649-663.
31 Gilbert DA, Altshuler KZ, Rago WV, e Coll.
Texas Medication Algorithm Project: definition, rationale and methods to
develop medication algorithms.
Journal of Clinical Psychiatry 1998;59:345-351.